AG0302-COVID‑19

AG0302-COVID‑19
Vaccine description
TargetSARS-CoV-2
Vaccine typeDNA
Clinical data
Routes of
administration		Intramuscular, Intradermal[1]

AG0302-COVID‑19 is a COVID-19 vaccine candidate developed by AnGes Inc.[2][3]

This candidate followed a previous one called AG0301-COVID‑19.[4]

References

  1. ↑ "Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 9 August 2021. Retrieved 6 October 2021.
  2. ↑ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. 3 December 2020. Retrieved 11 March 2021.{{cite journal}}: CS1 maint: url-status (link)
  3. ↑ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Archived from the original on 8 December 2020. Retrieved 11 March 2021.
  4. ↑ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.